RxDoctor Payments Data

Anil Chopra, MD

Internal Medicine · Glen Burnie, MDNPI 1205836236

Payments from drug & device makers

$9,438in general payments, 2019–2025

Across 510 payments — averaging $18.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • AstraZeneca$802
  • Pfizer$589
  • Bayer$485
  • Merck$358
  • plus $4K from 34 others

What the payments were for

  • Food & beverage$9,35899%
  • Education$801%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,438 in reported general payments places this provider in the 90th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$106,165
Medicare patients
296
Services billed
1,001

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala12$48,022
EliquisApixaban43$40,502
JanuviaSitagliptin Phosphate28$31,218
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$29,491
KerendiaFinerenone19$25,860
JardianceEmpagliflozin19$25,424
TrulicityDulaglutide17$21,876
TradjentaLinagliptin12$17,284
QuliptaAtogepant12$15,261
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog25$11,707
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$11,271
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$4,530
Atorvastatin Calcium285$3,628
Ezetimibe37$2,704
Rosuvastatin Calcium119$2,403

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$346$42,70831 claims
PfizerEliquis$589$40,50243 claims
MerckJanuvia$358$31,21828 claims
GSKTrelegy Ellipta$347$29,49141 claims
BayerKerendia$485$25,86019 claims
Lilly USA, LLCTrulicity$340$21,87617 claims
AbbVieQulipta$1,981$15,26112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Glen Burnie

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →